Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
NCT05014646
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
Scientists are testing how a medicine called leflunomide affects people with a certain kind of blood cancer. They want to see if it can help delay the symptoms of the cancer in African-American and European-American patients who are at a high risk. Leflunomide is a medicine that lowers the body's immune response.
Scientists are testing how a medicine called leflunomide affects people with a certain kind of blood cancer. They want to see if it can help delay the symptoms of the cancer in African-American and European-American patients who are at a high risk. Leflunomide is a medicine that lowers the body's immune response.
Third Opinion AI Generated Synopsis
Trial Summary
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
